Equities analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to post $175.32 million in sales for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for ABIOMED’s earnings, with the highest sales estimate coming in at $179.20 million and the lowest estimate coming in at $171.50 million. ABIOMED reported sales of $132.82 million during the same quarter last year, which indicates a positive year-over-year growth rate of 32%. The firm is scheduled to announce its next earnings report on Thursday, October 25th.

According to Zacks, analysts expect that ABIOMED will report full year sales of $768.18 million for the current year, with estimates ranging from $763.90 million to $774.12 million. For the next financial year, analysts expect that the firm will post sales of $974.85 million per share, with estimates ranging from $947.90 million to $1.00 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover ABIOMED.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 26th. The medical equipment provider reported $1.95 EPS for the quarter, beating the consensus estimate of $0.80 by $1.15. The company had revenue of $180.01 million for the quarter, compared to the consensus estimate of $173.87 million. ABIOMED had a net margin of 25.71% and a return on equity of 18.91%. The firm’s revenue was up 35.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.82 EPS.

Several research firms have issued reports on ABMD. BidaskClub cut shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. Piper Jaffray Companies increased their target price on shares of ABIOMED from $360.00 to $480.00 and gave the company an “overweight” rating in a research report on Friday, June 22nd. Zacks Investment Research cut shares of ABIOMED from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Jefferies Financial Group upped their price target on shares of ABIOMED to $460.00 and gave the company a “buy” rating in a research note on Tuesday, May 29th. Finally, ValuEngine lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 18th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $374.88.

Shares of NASDAQ:ABMD opened at $395.67 on Friday. The stock has a market cap of $17.63 billion, a P/E ratio of 161.50, a PEG ratio of 4.20 and a beta of -0.07. ABIOMED has a 12 month low of $155.57 and a 12 month high of $450.93.

In other ABIOMED news, COO David M. Weber sold 46,500 shares of the stock in a transaction on Monday, June 18th. The shares were sold at an average price of $442.63, for a total transaction of $20,582,295.00. Following the transaction, the chief operating officer now directly owns 189,657 shares of the company’s stock, valued at $83,947,877.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Michael R. Minogue sold 105,000 shares of the stock in a transaction on Thursday, June 21st. The shares were sold at an average price of $439.69, for a total transaction of $46,167,450.00. Following the transaction, the chairman now directly owns 481,150 shares in the company, valued at $211,556,843.50. The disclosure for this sale can be found here. Insiders sold 175,222 shares of company stock worth $75,382,784 in the last quarter. Company insiders own 3.50% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Cerebellum GP LLC purchased a new position in ABIOMED during the second quarter valued at $151,000. OLD Mutual Customised Solutions Proprietary Ltd. purchased a new position in ABIOMED during the second quarter valued at $164,000. Rampart Investment Management Company LLC purchased a new position in ABIOMED during the second quarter valued at $175,000. NewSquare Capital LLC purchased a new position in ABIOMED during the second quarter valued at $186,000. Finally, Piedmont Investment Advisors LLC purchased a new position in shares of ABIOMED in the second quarter worth about $196,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: Stop Order

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.